Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Rhode Island.
Press releases published on May 8, 2025
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
GlobeNewswire
·
May 8, 2025
IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in …
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer and Board Member. Huerga brings over …
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
GlobeNewswire
·
May 8, 2025
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% …
Stryker declares an $0.84 per share quarterly dividend
GlobeNewswire
·
May 8, 2025
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, …
Merus to Present at BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 8, 2025
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D …
Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
·
May 8, 2025
Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on- …
Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit
GlobeNewswire
·
May 8, 2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its Founder and Chief Scientific Officer, …
RAPT Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel …
Cassava Reports Q1 2025 Financials Results, Provides Business Update
GlobeNewswire
·
May 8, 2025
License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy $117.3 Million in Cash and Cash Equivalents at March 31, 2025 AUSTIN, Texas, May 08, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences …
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
May 8, 2025
-- Initial data from Phase 1/2 trial of PM359 for p47phox CGD expected in 2025 -- -- IND and/or CTA for PM577 for Wilson’s Disease on-track for 1H 2026 -- -- Unveiled potentially best-in-class program for AATD; IND and/or CTA filing targeted for mid-2026 …
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage …
Cue Biopharma to Host Virtual Investor Event on May 15, 2025
GlobeNewswire
·
May 8, 2025
Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a …
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
GlobeNewswire
·
May 8, 2025
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment …
Alzamend Neuro Announces Reverse Stock Split
GlobeNewswire
·
May 8, 2025
ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar …
OrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo Ventures
GlobeNewswire
·
May 8, 2025
OXFORD, England and MADISON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd., a leading organ medical technology company, completed a second closing of its private placement with investments from Intuitive Ventures, Terumo Ventures, and Piper Heartland …
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire
·
May 8, 2025
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a …
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
GlobeNewswire
·
May 8, 2025
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the …
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire
·
May 8, 2025
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025 Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary …
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 8, 2025
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential …
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell …